STAA

MKT CAP:$1B

STAAR Surgical Company

Market Cap

$1B

Healthcare·Medical - Instruments & Supplies·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$25.20+$1.60 (+6.76%)

Apr 21, 2026

Company Details

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian impla...

CEO

Warren Foust

IPO Date

Feb 24, 1992

Website

www.staar.com

Key Metrics TTM

Revenue

$231M

-32.4% YoY

Net Income

-$96M

EPS (Diluted)

-$1.95

Free Cash Flow

-$40M

Revenue / Share

$4.66

Gross Margin

73.9%

Operating Margin

-42.0%

Net Margin

-41.8%

FCF Margin

-17.1%

P/S

5.5x

P/E

—

Earnings Reports

Q4 2025

May 6, 2026

PENDING

FY 2025

Mar 3, 2026

$239M-23.7%EPS -$1.62

Q3 2025

Nov 5, 2025

$95M+6.9%EPS $0.18

Q2 2025

Aug 6, 2025

$44M-55.2%EPS -$0.34

Q1 2025

May 7, 2025

$43M-44.9%EPS -$1.10

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$59M	$45M	$7M
Q1 22	$63M	$49M	$12M
Q2 22	$81M	$64M	$17M
Q3 22	$76M	$60M	$14M
Q4 22	$64M	$50M	$964.0K
Q1 23	$74M	$58M	$3M
Q2 23	$92M	$71M	$9M
Q3 23	$80M	$64M	$6M
Q4 23	$76M	$61M	$10M
Q1 24	$77M	$61M	-$2M
Q2 24	$99M	$78M	$12M
Q3 24	$89M	$68M	$6M
Q4 24	$49M	$32M	-$28M
Q1 25	$43M	$28M	-$57M
Q2 25	$44M	$33M	-$30M
Q3 25	$95M	$78M	$18M

Valuation

Quarter	P/S	P/E
Q4 21	5.5x	51.3x
Q1 22	5.2x	43.2x
Q2 22	4.8x	37.5x
Q3 22	4.5x	33.3x
Q4 22	4.4x	32.5x
Q1 23	4.3x	39.5x
Q2 23	4.1x	50.5x
Q3 23	4.1x	64.7x
Q4 23	3.9x	58.9x
Q1 24	3.9x	82.2x
Q2 24	3.8x	75.7x
Q3 24	3.7x	57.8x
Q4 24	4.0x	—
Q1 25	4.5x	—
Q2 25	5.6x	—
Q3 25	5.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	$8M	$4M
Q1 22	-$5M	-$7M
Q2 22	$13M	$8M
Q3 22	$24M	$18M
Q4 22	$3M	-$1M
Q1 23	-$5M	-$8M
Q2 23	-$6M	-$9M
Q3 23	-$6M	-$15M
Q4 23	$32M	$29M
Q1 24	$22M	$16M
Q2 24	-$10M	-$17M
Q3 24	$4M	$15M
Q4 24	$642.0K	-$5M
Q1 25	-$6M	-$7M
Q2 25	-$27M	-$29M
Q3 25	$3M	$2M

Capital Expenditures

Quarter	CapEx
Q4 21	$5M
Q1 22	$3M
Q2 22	$5M
Q3 22	$6M
Q4 22	$4M
Q1 23	$3M
Q2 23	$3M
Q3 23	$9M
Q4 23	$3M
Q1 24	$5M
Q2 24	$6M
Q3 24	$11M
Q4 24	$6M
Q1 25	$1M
Q2 25	$2M
Q3 25	$883.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	+28.3%	+23.1%
Q1 22	+24.5%	+18.0%
Q2 22	+30.0%	+23.9%
Q3 22	+30.3%	+23.4%
Q4 22	+8.5%	+22.2%
Q1 23	+16.3%	+38.4%
Q2 23	+13.8%	+30.6%
Q3 23	+5.6%	+18.7%
Q4 23	+19.1%	+4.4%
Q1 24	+5.2%	+12.6%
Q2 24	+7.3%	+4.1%
Q3 24	+10.3%	+12.0%
Q4 24	-35.8%	+16.7%
Q1 25	-44.9%	+25.6%
Q2 25	-55.2%	-14.7%
Q3 25	+6.9%	-8.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$4M	6.1%
Q1 22	$4M	6.2%
Q2 22	$6M	7.1%
Q3 22	$6M	7.5%
Q4 22	$5M	7.8%
Q1 23	$6M	8.2%
Q2 23	$8M	9.1%
Q3 23	$9M	11.0%
Q4 23	$182.0K	0.2%
Q1 24	$6M	8.2%
Q2 24	$9M	9.1%
Q3 24	$7M	8.1%
Q4 24	$5M	9.5%
Q1 25	$6M	14.1%
Q2 25	$8M	17.6%
Q3 25	$8M	8.6%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 21	$9M	$11M	$17M
Q1 22	$8M	$12M	$17M
Q2 22	$9M	$14M	$24M
Q3 22	$10M	$14M	$23M
Q4 22	$10M	$15M	$24M
Q1 23	$10M	$18M	$26M
Q2 23	$12M	$18M	$32M
Q3 23	$11M	$19M	$27M
Q4 23	$11M	$17M	$23M
Q1 24	$13M	$23M	$27M
Q2 24	$12M	$24M	$31M
Q3 24	$14M	$22M	$27M
Q4 24	$12M	$21M	$26M
Q1 25	$14M	$24M	$25M
Q2 25	$10M	$21M	$26M
Q3 25	$9M	$21M	$23M

Revenue Segments

Quarter	Cataract Intraocular Lenses	Implantable Collamer Lenses	Other Surgical Products
Q1 22	$3M	$59M	$2M
Q2 22	$3M	$78M	$632.0K
Q3 22	$2M	$72M	$2M
Q4 22	$2M	$61M	$884.0K
Q1 23	$1M	$71M	$1M
Q2 23	$40.0K	$93M	-$846.0K
Q3 23	$221.0K	$81M	-$540.0K
Q4 23	—	$75M	$2M
Q1 24	—	$77M	$205.0K
Q2 24	—	$99M	—
Q3 24	—	$89M	—
Q1 25	—	$41M	$1M

Revenue by Geography

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$193M	$0	$193M
Q2 22	$202M	$0	$202M
Q3 22	$129M	$82M	$211M
Q4 22	$86M	$125M	$212M
Q1 23	$90M	$114M	$204M
Q2 23	$95M	$97M	$192M
Q3 23	$127M	$61M	$188M
Q4 23	$183M	$38M	$221M
Q1 24	$224M	$21M	$245M
Q2 24	$193M	$42M	$235M
Q3 24	$164M	$72M	$236M
Q4 24	$144M	$86M	$230M
Q1 25	$173M	$50M	$223M
Q2 25	$167M	$23M	$190M
Q3 25	$176M	$17M	$193M
Q4 25	$153M	$34M	$188M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	49M	-0.2%	+1.4%
Q1 22	49M	-0.4%	+0.2%
Q2 22	49M	-0.1%	-0.5%
Q3 22	50M	+0.7%	-0.1%
Q4 22	49M	-0.3%	-0.2%
Q1 23	50M	+0.2%	+0.4%
Q2 23	50M	+0.0%	+0.6%
Q3 23	49M	-0.3%	-0.4%
Q4 23	49M	-0.3%	-0.3%
Q1 24	49M	-0.7%	-1.2%
Q2 24	50M	+1.8%	+0.6%
Q3 24	50M	-0.2%	+0.7%
Q4 24	49M	-0.9%	+0.0%
Q1 25	49M	+0.2%	+0.9%
Q2 25	50M	+0.4%	-0.6%
Q3 25	50M	0.0%	-0.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$73.2K	806
Q1 22	$78.4K	806
Q2 22	$100.6K	806
Q3 22	$94.3K	806
Q4 22	$66.4K	964
Q1 23	$76.3K	964
Q2 23	$95.8K	964
Q3 23	$83.3K	964
Q4 23	$68.4K	1K
Q1 24	$69.4K	1K
Q2 24	$88.8K	1K
Q3 24	$79.5K	1K
Q4 24	$40.4K	1K
Q1 25	$35.2K	1K
Q2 25	$36.6K	1K
Q3 25	$78.2K	1K

Revenue / Employee